CN100579579C - 抗癌及抗感染性疾病组合物及其使用方法 - Google Patents

抗癌及抗感染性疾病组合物及其使用方法 Download PDF

Info

Publication number
CN100579579C
CN100579579C CN200380104308A CN200380104308A CN100579579C CN 100579579 C CN100579579 C CN 100579579C CN 200380104308 A CN200380104308 A CN 200380104308A CN 200380104308 A CN200380104308 A CN 200380104308A CN 100579579 C CN100579579 C CN 100579579C
Authority
CN
China
Prior art keywords
cell
pathogenic
virus
baculovirus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200380104308A
Other languages
English (en)
Chinese (zh)
Other versions
CN1717250A (zh
Inventor
W·M·卡瓦诺
D·L·斯隆
M·L·麦克占
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Chiron Corp filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN1717250A publication Critical patent/CN1717250A/zh
Application granted granted Critical
Publication of CN100579579C publication Critical patent/CN100579579C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200380104308A 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法 Expired - Fee Related CN100579579C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/416,660 2002-10-01
US60/414,649 2002-10-01
US41666002P 2002-10-07 2002-10-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910253113A Division CN101721697A (zh) 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法

Publications (2)

Publication Number Publication Date
CN1717250A CN1717250A (zh) 2006-01-04
CN100579579C true CN100579579C (zh) 2010-01-13

Family

ID=32069951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200380104308A Expired - Fee Related CN100579579C (zh) 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法

Country Status (7)

Country Link
US (1) US7122546B2 (enExample)
EP (1) EP1549636A1 (enExample)
JP (1) JP2006504714A (enExample)
CN (1) CN100579579C (enExample)
AU (1) AU2003267722A1 (enExample)
CA (1) CA2495698A1 (enExample)
WO (1) WO2004031174A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495708A1 (en) * 2002-11-08 2004-05-21 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives as ligands for gabaa receptors
JP2006517958A (ja) 2003-02-19 2006-08-03 ニューロジェン・コーポレイション アリール酸ピリミジニルメチルアミド、ピリダジニルメチルアミドおよび関連化合物
AU2004261591A1 (en) * 2003-07-25 2005-02-10 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
AU2008205169B2 (en) 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
RU2705556C2 (ru) * 2012-12-21 2019-11-07 Келверум Инк. Нереплицируемые происходящие от вирусов частицы и их применение
AU2018244916B2 (en) 2017-03-30 2021-11-18 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US6982268B2 (en) 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2495708A1 (en) 2002-11-08 2004-05-21 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives as ligands for gabaa receptors
WO2004107863A1 (en) 2003-05-05 2004-12-16 Neurogen Corporation Sustituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of different baculovirus inactivation procedures on theintegrity and immunogenicity of porcine parvovirus-likeparticles. Rueda et al.Vaccine,Vol.19. 2001 *
Photochemical inactivation of recombinant baculovirus. Weightman et al.Journal of Virological Methods,Vol.81. 1999 *

Also Published As

Publication number Publication date
WO2004031174A8 (en) 2005-04-21
US20040077653A1 (en) 2004-04-22
JP2006504714A (ja) 2006-02-09
AU2003267722A8 (en) 2004-04-23
AU2003267722A1 (en) 2004-04-23
WO2004031174A1 (en) 2004-04-15
EP1549636A1 (en) 2005-07-06
US7122546B2 (en) 2006-10-17
CA2495698A1 (en) 2004-04-15
CN1717250A (zh) 2006-01-04

Similar Documents

Publication Publication Date Title
AU2009230821B2 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
CN102268454B (zh) 一种psma重组腺相关病毒载体及其构建方法与应用
US8481297B2 (en) Compositions and methods of use of an oncolytic vesicular stomatitis virus
Atkins et al. Therapeutic and prophylactic applications of alphavirus vectors
JP6698881B2 (ja) 新規の免疫刺激性ベクター系
JP7159304B2 (ja) 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性アデノウイルス、医薬組成物、およびそれらの使用
WO2000055345A9 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
CN100579579C (zh) 抗癌及抗感染性疾病组合物及其使用方法
US9241998B2 (en) Methods and compositions for treatment of cancer using oncolytic RSV activity
ES2540958T3 (es) Partículas de replicón de alfavirus que expresan TRP2
JP4708027B2 (ja) 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US6872385B2 (en) Adjuvant preparation for the induction of specific immunity
ES2313723T3 (es) Vacunas del virus de la inmunodeficiencia humana y agentes terapeuticos que contienen mutantes de delecion de nef de hiv-1 deteriorados en replicacion.
JP2006517184A5 (enExample)
WO2004037182A2 (en) Active specific immunotherapy of cancer metastasis
US20070264281A1 (en) Vaccination Vectors Derived From Lymphotropic Human Herpes Viruses 6 and 7
Dorostkar et al. An endogenous immune adjuvant released by necrotic cells for enhancement of DNA vaccine potency
Berthold et al. Intrinsic interference caused by hepatitis sera
Epstein The Florey Lecture, 1986-Vaccine prevention of virus-induced human cancers
Liu et al. Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX
Kharazi et al. Effect of Endogenously Produced IL-10 on Secretion of IL-12p70 by Interferon-alpha Dendritic Cells
Brenner et al. T-Cell Therapies for EBV-Associated Malignancies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100113

Termination date: 20121001